Introduction {#sec1-1}
============

Stable genetic alterations in VHL gene (von Hippel-Lindau) followed by HIF (hypoxia inducible factor) and vascular endothelial growth factor (VEGF) overexpression are known to contribute to the development of renal cell carcinoma (Badewiijns et al., 2010). It should be noted that the pVHL mutations do not affect the cancer prognosis and disease outcome (Choueiri et al., 2008). There is also no association between the pVHL status and expression of tumor markers (Badewiijns et al., 2010; Spirina et al., 2008; Yumazov et al., 2016). In addition, there is evidence that cancer progression is associated with the decreased HIF-1α gene expression in tumor tissue, accompanied by high levels of HIF-2α (Sakamoto et al., 2009; Sourbier et al., 2012) and carbonic anhydrase IX (CAIX) mRNA (Driessen et al., 2006). The transcription factor κB (NF-κB) is one of the important intracellular agents, regulating the processes of proliferation and apoptosis in renal cancer (Fan et al., 2008).

Signal transduction involves binding to tyrosine kinase receptor VEGFR2 and results in AKT-mTOR pathway stimulation (Badalian et al., 2007; Szajewski et al., 2015). The main AKT substrates are variety of proteins involved in cell growth, proliferation and apoptosis (c-RAF (serine/threonine-protein kinase), GSK-3-beta (glycogen synthase kinase-3-beta)) (Guo et al., 2015; Spirina et al., 2015). The pathway is antagonized by various factors including PTEN (Gao et al., 2005; Schultz et al., 2011). It is known that hypoxia-inducible transcription factor (HIF-1) can stimulate activity of m-TOR (Hudson et al., 2002).

The AKT/mTOR signaling pathway activation has been shown in different tumors (Pópulo et al., 2012). There have been contradictory results about the association of investigated molecular markers with the kidney cancer growth and progression of kidney cancer. Almatore et al., (2005) reported that the activation of AKT/m-TOR signaling cascade was detected in only 40% of kidney tumor cells. Recently there has been evidence of overexpression of AKT signaling pathway with an increased content of its components in tissues of clear cell renal carcinoma (RCC) (Li et al., 2013; Akbani et al., 2014; Spirina et al., 2015).

Pazopanib, a targeted tyrosine kinase inhibitor, is widely used for treating patients with advanced renal cell carcinoma. However, there have been no published reports indicating the effects of tyrosine kinase inhibitors on molecular markers in renal cell carcinoma. The aim of the study was to investigate the expression and content of transcription, growth factors and components of the AKT/m-TOR signaling pathway in kidney cancer patients before and after targeted therapy with pazopanib.

Materials and Methods {#sec1-2}
=====================

Material and methods of investigation {#sec2-1}
-------------------------------------

A total of 157 patients with RCC were enrolled in the study. The retrospective study included patients with histopathologically verified RCC, admitted to and nephrectomised at the Cancer Research Institute, Tomsk National Research Center, Russian Academy of Medical Sciences, Tomsk, Russian Federation. The patients underwent a physical examination, chest radiography, and computer tomography (CT) of the abdomen. When vena cava tumour thrombus invasion was suspected, cavography or magnetic resonance imaging (MRI) was performed. Patients with skeletal-associated pain or elevated serum alkaline phosphatase were assessed with bone scintigraphy. The patients were followed-up according to a program including regular clinical and radiological examinations. The median age of the patients was 57 years. The treatment for kidney cancer depends on the size of the cancer and whether it has spread to other parts of the body.

Localized RCC (T1-3N0M0) was diagnosed in 90 patients and metastatic RCC (T2-4N0-1M1) in 63 patients. All patients with localized RCC underwent surgery (partial nephrectomy or simple nephrectomy) and then followed-up according to a program including regular clinical and radiological examinations. Patients with metastatic RCC received 2 cycles of preoperative targeted therapy with pazopanib at a dose of 800 mg daily, for 2 months. Tumor response to targeted therapy was evaluated according to RECIST criteria. All patients underwent radical nephrectomy. Diagnosis was verified on the basis of biopsy results.

The study was approved by the Local Committee for Medical Ethics and all patients provided written informed consent. Tumor tissue samples and histologically normal tissue samples adjacent to tumors were used for investigation. Specimens were reviewed separately by two independent pathologists.

RNA extraction {#sec2-2}
--------------

The postoperative tumor samples were incubated in RNAlater solution (Ambion, USA) for 24-hours at + 4 °C and then stored at -80°C. Total RNA was extracted using RNeasy Mini Kit (Qiagen).

RT-qPCR. PCR was conducted in 25 μl reaction volumes containing 12.5 μl BioMaster HS-qPCR SYBR Blue (2X) ("Biolabmix" Russia) and 300 nanoM of each primers. CAIX: F 5´-GTTGCTGTCTCGCTTGGAA-3´, R 5´-CAGGGTGTCAGAGAGGGTGT-3´; HIF-1´: F 5´- CAAGAACCTACTGCTAATGCCA-3´, R 5´- TTTGGTGAGGCTGTCCGA-3´; EPAS1: F 5´- TGGAGTATGAAGAGCAAGCCT-3´, R 5´-GGGAACCTGCTCTTGCTGT-3´; NFKB1: F 5´-CGTGTAAACCAAAGCCCTAAA-3´, R 5´-AACCAAGAAAGGAAGCCAAGT-3´; RELA: F 5´-GGAGCACAGATACCACCAAGA-3´, R 5´-GGGTTGTTGTTGGTCTGGAT-3´; VEGFA: F 5´-AGGGCAGAATCATCACGAA-3´, R 5´-TCTTGCTCTATCTTTCTTTGGTCT-3´; KDR: F 5´-AACACAGCAGGAATCAGTCA-3´, R 5´-GTGGTGTCTGTGTCATCGGA-3´; 4E-BP1: F 5´- CAGCCCTTTCTCCCTCACT -3´, R 5´- TTCCCAAGCACATCAACCT -3´; AKT1: F 5´- CGAGGACGCCAAGGAGA -3´, R 5´- GTCATCTTGGTCAGGTGGTGT -3´; C-RAF: F 5´- TGGTGTGTCCTGCTCCCT -3´, R 5´- ACTGCCTGCTACCTTACTTCCT -3´; GSK3b: F 5´- AGACAAGGACGGCAGCAA -3´, R 5´- TGGAGTAGAAGAAATAACGCAAT -3´; 70S kinase alpha: F 5´- CAGCACAGCAAATCCTCAGA -3´, R 5´- ACACATCTCCCTCTCCACCTT -3´; m-TOR: F 5´- CCAAAGGCAACAAGCGAT-3´, R 5´- TTCACCAAACCGTCTCCAA -3´; PDK1: F 5´- TCACCAGGACAGCCAATACA -3´, R 5´- CTCCTCGGTCACTCATCTTCA -3´; GAPDH: F 5´- GGAAGTCAGGTGGAGCGA-3´, R 5´-GCAACAATATCCACTTTACCAGA-3´. A pre-incubation at 95°C for 10 min was to activate the Hot Start DNA polymerase and denature DNA, and was followed by 45 amplification cycles of 95°C denaturation at 95 0 for 10 sec, 60°C annealing at 60 0 for 20 sec (iCycler iQ™, BioRad).

The fold changes were calculated by ΔΔC~t~ method (the total ΔΔC~t~ = fold of cancerous/normal tissue gene level), using normal tissue. A ratio of specific mRNA/GADPH (GADPH as a respective control) amplification was then calculated.

VEGF, VEGFR2, CAIX, HIF-1α, HIF-2, NF-κB p50 и NF-κB p65 determination. HIF-1α and NF-κΒ (p50 and p65) expressions were measured using Caymanchem ELISA kits (USA) in Anthos 2020 ELISA-microplate reader (Biochrom, UK). Nuclear extracts were prepared and purified according to manufacturer's instructions. CAIX, HIF-2α determination was performed using Cusabio Elisa kits (China).

Determination of expression levels of AKT/m-TOR signaling pathway components Electrophoresis {#sec2-3}
--------------------------------------------------------------------------------------------

SDS-PAGE (Laemmli) was used.

Western Blot Analysis {#sec2-4}
---------------------

The protein was transferred to 0.2-/xm pore-sized PVDF membrane (GE Healthcare, UK), either at 150 mA or 100 V for 1 h by using a Bio-Rad Mini Trans-Blot electrophoresis cell. The membrane was incubated in a 1:2500 dilution of monoclonal mouse anti-human phospho-PTEN (Ser380), AKT (pan), phospho -AKT (T308), phospho-GSK-3-beta (Ser9), phospho-PDK1 (Ser241), phospho-c-Raf (Ser259), m-TOR, phospho-mTOR (Ser2448), phospho-p70 S6 (Ser371), phospho-4E-BP1 (Thr37/46) (Cell Signaling, USA) at 4 º overnight. PVDF samples were incubated in Amersham ECL western blotting detection analysis system (Amersham, USA). The results were standardized using the beta-actin expression in a sample and were expressed in percentages to the protein content in non-transformed tissues. The level of protein in normal non-altered tissue was indicated as 100%.

Statistical analysis {#sec2-5}
--------------------

Statistical analysis was performed using SPSS 19.0 software. The gene expression was presented as mean ± error of the mean. Data were expressed as median and ranges. Either a Student's t-test or Mann-Whitney test was used for comparing differences in mean values. Correlation analysis of data was carried out using a Spearman Rank Correlation test.

Results {#sec1-3}
=======

Expression and content of transcription and growth factors in patients with kidney cancer are linked to the metastasis development. The level of HIF-2α mRNA was 3 times higher in patients with metastatic RCC than in patients with localized RCC ([Figure 1](#F1){ref-type="fig"}). The expression level of mRNA of HIF-1-dependent proteins was increased in patients with metastatic RCC. In patients with metastatic RCC, a 8.5-, 19.8- and 13.4-fold increase was observed in the VEGF, CAIX and VEGFR2 expressions, respectively.

![Expression of NF-kB p50, NF-kB p65, HIF-2, HIF-1α (a), VEGF, peцeптopa VEGFR2 и, CAIX (b) in cancer tissues, M -- is a stage of cancer: 0 -- non-metastatic cancer, 1 -- metastatic cancer. In patients with metastatic RCC, a 8.5-, 19.8- and 13.4-fold increase was observed in the VEGF, CAIX and VEGFR2 expressions, respectively. The study showed that the level of HIF-1α transcription factor was 1.5 times higher in patients with disseminated RCC compared to that observed in patients with localized RCC.](APJCP-18-2977-g001){#F1}

The study showed that the level of HIF-1α transcription factor was 1.5 times higher in patients with disseminated RCC compared to that observed in patients with localized RCC ([Figure 2](#F2){ref-type="fig"}). The levels of VEGF and VEGFR2 receptor were respectively 2.3 and 1.78 times higher in metastatic compared to non-metastatic cancer tissues. On the contrary, the CAIX level was 1.5 times lower in patients with metastatic disease compared to those who had localized cancer.

![Levels of NF-kB p50, NF-kB p65, HIF-1α (a); HIF-2, CAIX b); VEGF. VEGFR2 (c) in Cancer Tissues, M -- is a Stage of Cancer: 0 -- non-metastatic cancer, 1 -- metastatic cancer. The levels of VEGF and VEGFR2 receptor were respectively 2.3 and 1.78 times higher in metastatic compared to non-metastatic cancer tissues. On the contrary, the CAIX level was 1.5 times lower in patients with metastatic disease compared to those who had localized cancer.](APJCP-18-2977-g002){#F2}

Expression and content of AKT m-TOR signaling pathway components in kidney cancer patients. A 7.4- and 1.87- fold increase in AKT mRNA and PDK1 levels, respectively, was revealed in patients with hematogenous metastasis ([Table 1](#T1){ref-type="table"}). In addition, a 2.2-fold decrease in GSK-3ß expression was observed in tissue of metastatic RCC compared to that of localized RCC. The PTEN mRNA level was significantly lower in patients with distant metastases compared to patients with localized cancer.

###### 

Relative Expression and Content of PTEN, AKT, GSK-3ß, PDK1, c-RAF, m-TOR, 70 S6 Kinase and 4E-BP1 in Cancer Tissues of Kidney

  Parameter, Relative units                           n                                                Localized cancer   Metastatic cancer                             Parameter, %              Localized cancer        Metastatic cancer
  --------------------------------------------------- ------------------------------------------------ ------------------ --------------------------------------------- ------------------------- ----------------------- -----------------------------------------------------
  AKT/m-TOR signaling pathway components expression   AKT/m-TOR signaling pathway components content                                                                                                                      
  PTEN                                                33                                               22.45±9.4          8.34±6.70[\*](#t1f1){ref-type="table-fn"}     phospho -PTEN             99.7 (70.4-139.2)       55.3 (55.2-57.0)[\*](#t1f1){ref-type="table-fn"}
  AKT                                                 33                                               9.84±4.76          72.97±40,12[\*](#t1f1){ref-type="table-fn"}   AKT (pan)                 139.95 (110.68-229.4)   160.35 (112.3-175.4)
                                                                                                                                                                        phospho -AKT (308)        105.1 (76.1-156.58)     73.1 (55.9-84.7)[\*](#t1f1){ref-type="table-fn"}
                                                                                                                                                                        phospho -AKT (473)        118.6 (93.2-164.1)      85.22 (53.44-106.7)[\*](#t1f1){ref-type="table-fn"}
  GSK-3-beta                                          33                                               27.65±9.71         12.4±3.8[\*](#t1f1){ref-type="table-fn"}      phospho -GSK-3-b          156.1 (106.85-250.5)    147.5 (97.4-196.9)
  PDK1                                                33                                               16.13±3.19         30.2±17.3[\*](#t1f1){ref-type="table-fn"}     phospho -PDK1             132.0 (102.35-168.0)    119.2 (111.7-132.6)
  c-RAF                                               33                                               24.01±8.33         41.13±10.83                                   phospho -c-Raf            157.1 (102.9-240.75)    146.35 (75.8-164.9)
  m-TOR and its substrates expression                 m-TOR and its substrates expression content                                                                                                                         
  m-TOR                                               33                                               20.68±9.91         54.83±23.09                                   m-TOR                     158.6 (90.35-218.0)     129.4 (78.8-138.4)
  70 S6 kinase                                        33                                               31.98±12.82        32.6±17.22                                    phospho -mTOR (Ser2448)   128.1 (93.0-205.6)      108.1 (81.7-160.4)
                                                                                                                          phospho-p70 S6 (S371)                         93.6 (67.1-117.8)         101.9 (39.0-173.7)      
                                                                                                                          phospho-p70 S6 kinase (T389)                  131.0 (78.1-188.7)        128.0 (105.4-136.8)     
  4E-BP1                                              33                                               12.15±5.4          33.32±11.05[\*](#t1f1){ref-type="table-fn"}   phospho-4E-BP1            109.7 (83.4-155.5)      101.2 (93.8-108.6)

\- Level of significance compared to the localized kidney cancer patients; p\<0.05

The 4E-BP1 expression was also associated with hematogenous metastases, being 2.7 times higher in patients with metastatic renal cancer than in localized cancer. The AKT/m-TOR signaling pathway components were determined in cancer patients. The activation of this pathway was found in kidney cancers by increase of AKT, its phosphorylated form, proteinkinase m-TOR, glycogen regulator GSK-3-ß and transcription inhibitor 4E-BP1 ([Figure 3](#F3){ref-type="fig"}). It was noted that the development of distant metastasis was accompanied by a significant decrease of the PTEN and phospho-AKT content in 1.8 and1.4 fold, respectively, in the tumor tissues compared to the non-metastatic ones.

![Immunoblots of AKT/m-TOR Components in Kidney Cancer Tissues. a -- AKT, phospho-PDK1, phospho-c-Raf, phospho-GSK-3beta and phospho-PTEN level in non transformed (1) and cancer (2) tissues; b -- m-TOR, phospho-m-TOR, 70S 6 kinase and 4E-BP1 levels in non transformed (1) and cancer (2) tissues. Note: The results were standardized using the beta-actin expression in a sample and were expressed in percentages to the protein content in non-transformed tissues. The level of protein in normal non-altered tissue was indicated as 100%. It is found the activation of AKT/m-TOR signaling pathway in kidney cancers by increase of AKT, its phosphorylated form, proteinkinase m-TOR, glycogen regulator GSK-3-ß and transcription inhibitor 4E-BP1.](APJCP-18-2977-g003){#F3}

Effect of targeted therapy with pazopanib on expression and content of transcription, growth factors and components of the AKT / m-TOR signaling pathway.

Targeted agents are currently administered for patients with metastatic kidney cancer. In a study involving 63 patients with metastatic renal cancer, therapy with pazopanib resulted in partial tumor regression in 26.9% of cases, disease stable in 61.5%, and progression in 11.5% of cases. Expression levels of growth and transcription factors tended to decrease after therapy with pazopanib ([Table 2](#T2){ref-type="table"}). The HIF-2α expression was found to be 48 times lower after therapy than before therapy.

###### 

Expression and Content of Transcription Factors NF-κB p65, NF-κB p50, HIF-1α, HIF-2α in Disseminated Cancer Tissues of Kidney before (Untreated Group) and after Pazopanib Targeted Therapy (Pazopanib Treated Group)

  Parameter, Relative units          n                               Untreated group                 Pazopanib treated group                     Parameter                             Untreated group       Pazopanib treated group
  ---------------------------------- ------------------------------- ------------------------------- ------------------------------------------- ------------------------------------- --------------------- --------------------------------------------------
  Transcription factors expression                                   Transcription factors content                                                                                                           
  NF-kB p65                          33                              3.1±1.5                         0.98±0.66                                   NF-kB p65, Units/mg protein in well   9.8 (6.6-15.3)        4.6 (3.9-9.0)[\*](#t2f1){ref-type="table-fn"}
  NF-kB p50                          33                              31.1±19.3                       1.16±0.85                                   NF-kB p50, Units/mg protein in well   7.0 (5.12-20.62)      4.47 (3.34-6.33)[\*](#t2f1){ref-type="table-fn"}
  HIF-1a                             33                              3.0±1.22                        0.48±0.27                                   HIF-1a, Units/mg protein in well      6.2 (3.1-7.1)         1.0 (0.34-2.0)[\*](#t2f1){ref-type="table-fn"}
  HIF-2a                             33                              17,8±10,9                       0,37±0,23[\*](#t2f1){ref-type="table-fn"}   HIF-2a, pg/mg of protein              332,0 (246,0-551,9)   352,8 (300,0-1007,2)
  VEGF, VEGFR2 and CAIX expression   VEGF, VEGFR2 and CAIX content                                                                                                                                           
  VEGF                               33                              4.9±1.9                         0.3±0.2                                     VEGF, pg/mg of protein                16.6 (10.8-52.5)      9.2 (8.52-12.4)
  VEGFR2                             33                              9.1±6.9                         1.2±0.7                                     VEGFR2, pg/mg of protein              43.3 (23.5-62.5)      29.8 (19.1-41.6)
  CAIX                               33                              11.5±6.13                       3.7±3.7                                     CAIX, pg/mg of protein                246.9 (111.2-523.6    20.5 (14.8-81.5)[\*](#t2f1){ref-type="table-fn"}

\- Level of significance compared to the patients untreated with pazopanib; p\<0.05

Therapy with pazopanib resulted in a 2.1-, 1.6- and 6.2- fold reduction in NF-κB p65, NF-κB p50 and HIF-1α levels, respectively. The level of CAIX was 12 times lower after therapy than before therapy.

We revealed a 3-fold increase in AKT expression in cancer tissues after treatment ([Table 3](#T3){ref-type="table"}). Signaling pathway activation was also accompanied by a 2-fold increase in GSK-3beta mRNA level compared to that observed before treatment.

###### 

Relative Expression and Content of PTEN, AKT, GSK-3ß, PDK1, c-RAF, m-TOR, 70 S6 Kinase and 4E-BP1 in Disseminated Cancer Tissues of Kidney before (Untreated Group) and after Pazopanib Targeted Therapy (Pazopanib Treated Group)

  Parameter, Relative units                           n                                                Untreated group   Pazopanib treated group                      Parameter, %                   Untreated group        Pazopanib treated group
  --------------------------------------------------- ------------------------------------------------ ----------------- -------------------------------------------- ------------------------------ ---------------------- -----------------------------------------------------
  AKT/m-TOR signaling pathway components expression   AKT/m-TOR signaling pathway components content                                                                                                                        
  PTEN                                                33                                               1.0±0.5           2.0±0.5                                      phospho -PTEN                  96.8 (64.9-112.45)     56.14 (55.2-57.0)[\*](#t3f1){ref-type="table-fn"}
  AKT                                                 33                                               34.7±23.7         105.0±41.6[\*](#t3f1){ref-type="table-fn"}   AKT (pan)                      129.7 (103.8-223.75)   212.7 (175.4-250.1)
                                                                                                                                                                      phospho -AKT (308)             105.1 (73.1-156.6)     70.3 (55.9-84.7)[\*](#t3f1){ref-type="table-fn"}
                                                                                                                                                                      phospho -AKT (473)             101.95 (72.5-137.7)    118.9 (105.2-132.6)
  GSK-3-beta                                          33                                               22.7±8.1          46.5±24.6[\*](#t3f1){ref-type="table-fn"}    phospho -GSK-3-b               144.8 (101.7-232.5)    199.8 (147.5-252.1)
  PDK1                                                33                                               21.1±10.1         74.5±34.5                                    phospho -PDK1                  129.5 (86.9-162.4)     144.3 (132.6-156.0)
  c-RAF                                               33                                               35.2±9.9          52.6±36.6                                    phospho -c-Raf                 145.9 (93.6-240.7)     155.6 (93.6-240.7)
  m-TOR and its substrates expression                 m-TOR and its substrates expression content                                                                                                                           
  m-TOR                                               33                                               33.8±15.5         25.1±10.2                                    m-TOR                          157.3 (75.35-218.0)    133.9 (129.4-138.4)
  70 S6 kinase                                        33                                               32.1±14.2         13.1±12.7                                    phospho -mTOR (Ser2448)        116.7 (79.5-173.5)     179.0 (160.4-197.7)
                                                                                                                                                                      phospho-p70 S6 (S371)          90.35 (44.7-117.8)     175.2 (101.9-248.5)[\*](#t3f1){ref-type="table-fn"}
                                                                                                                                                                      phospho-p70 S6 kinase (T389)   109.7 (83.4-155.5)     101.2 (93.8-108.6)
  4E-BP1                                              33                                               18.4±7.9          49.8±23.7                                    phospho-4E-BP1                 109.7 (83.4-155.5)     101.2 (93.8-108.6)

\- Level of significance compared to the patients untreated with pazopanib; p\<0.05;

The AKT and phosphorylated AKT (T308) expressions were 1.5 times higher after treatment than before treatment. In addition, a 1.9-fold increase in the level of phospho-p70 S6 (S371) kinase was also observed. The use of targeted therapy with tyrosine kinase inhibitors led to a1.7-fold reduction in the level of phospho-PTEN

Discussion {#sec1-4}
==========

Carbonic anhydrase IX (CAIX) is known to be a HIF-1α- dependent protein (Badewiijns et al., 2010). Changes in mRNA and protein levels of HIF-1α and CAIX in metastasis development were shown to be multidirectional. These results were similar to data shown by Linden et al., (2008). The authors found that in patients with clear-cell renal cell carcinoma, dissemination of tumor cells was associated with low HIF-1α expression and high content of the corresponding protein. We also revealed the HIF-1α mRNA suppression in metastatic cancer, accompanied by a high content of the HIF-1α protein.

Moreover, the increased CAIX mRNA level led to decrease in the content of its protein. The CAIX is involved in the regulation of various carcinogenic processes (Sourbier et al., 2012). These changes are likely can affect the growth and proliferation of tumor cells.

The development of haematogenous metastases from RCC is accompanied by the increased HIF-2α expression with the high level of corresponding protein. It is known that the activation of HIF-2 leads to a modification of proliferative potential of cancer cells (Driessen et al., 2006; Linden et al., 2008). This phenomenon is likely to be caused by specific peculiarities of tumor cells. We suppose that the metastatic phenotype activation and cancer progression are the main stages of cancerogenesis and they are closely related to the HIF-2α expression.

This marker is likely to be a predictor of unfavorable outcome. Therefore, 4E-BP1 mRNA could be an indicator of tumor aggressiveness, that was consistent with other recent studies (Biswas et al., 2010; Gerlinger et al., 2012; Darwish et al., 2013).

These data allow us to conclude that the metastasis activation is followed by a stimulation of AKT/m-TOR signaling pathway with PTEN deficiency. So, they can be the potential targets for pazopanib targeted therapies.

Effect of targeted cancer therapy on molecular markers is currently associated with its efficacy. We studied the relationship between the level of transcription/growth factors and their expression in kidney cancer. The changes in the levels of molecular markers and their expression were revealed. Our data indicated that the effect of pazopanib was associated with decreased expression and content of transcription factors responsible for tumor angiogenesis. We showed the expression and content of molecular markers in renal tumor untreated and treated with pazopanib. The progression of kidney cancer occurred due to a high levels of HIF-2α mRNA and its protein. Targeted therapy with pazopanib resulted in a decrease in the level of HIF-2α mRNA, thus indicating the effectiveness of this treatment. This positive effect was also confirmed by the analysis of NF-κB p65, NF-κB p50 and HIF-1α transcription factors. Reduction in these markers led to decreased production of transcription factors including CAIX.

The altered expression of AKT/m-TOR signaling pathway components also belongs to the molecular characteristics of RCC metastasis development. Although these facts are mailny theoretical, they may be useful in evaluating potential tumor markers for predicting disease outcome. It was detected an increase of GSK-3ß and AKT mRNA levels at low rates of corresponding proteins in cancer tissues after targeted therapy. The targeted therapy did not influence the level of PTEN, which remained low after therapy.

In conclusion, molecular events responsible for the development of cancer were shown to be the potential markers for targeted therapy. The use of tyrosine kinase inhibitors resulted in decreased expression of angiogenic factors. The level of p70 S6 (S371) was increased, while the level of AKT and GSK-3ß was decreased. The impact of this treatment on the PTEN content was not identified. Further studies are necessary to evaluate the impact of the targeted therapy on molecular markers, thus allowing the efficacy of therapy to be increased.
